Narcolepsy & Idiopathic Hypersomnia
Excessive daytime sleepiness that has not responded to better sleep hygiene is not a willpower problem. It is a neurologic signal that deserves a precise diagnosis.
What we mean when we say Narcolepsy & Idiopathic Hypersomnia.
Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness, disrupted nighttime sleep, and — in Type 1 narcolepsy — cataplexy (sudden loss of muscle tone triggered by emotion). Type 1 is associated with low CSF orexin/hypocretin levels and is believed to be autoimmune in origin. Type 2 lacks cataplexy and orexin loss is less consistent.
Idiopathic Hypersomnia (IH) shares the symptom of excessive daytime sleepiness but lacks the rapid REM transitions characteristic of narcolepsy. IH frequently presents with severe sleep inertia and long, unrefreshing sleep periods.
Diagnosis requires polysomnography followed by Multiple Sleep Latency Testing (MSLT), with specific protocols and interpretation requirements that are frequently misapplied. Many patients are misdiagnosed with depression, sleep apnea (which may coexist but not explain the picture), or simply 'poor sleep hygiene.'
Narcolepsy affects approximately 1 in 2,000 people globally (50 per 100,000). Idiopathic hypersomnia prevalence is less well characterized but believed to be similar or higher.
Why Narcolepsy & Idiopathic Hypersomnia gets missed.
Narcolepsy and Idiopathic Hypersomnia are missed not because they're rare but because the testing required to diagnose them is rarely done correctly. Excessive daytime sleepiness gets attributed to depression, anxiety, sleep apnea, or 'poor sleep hygiene' — and the MSLT and structured cataplexy evaluation that would identify the actual condition get bypassed.
- 01Excessive daytime sleepiness is the presenting complaint, but the workup rarely proceeds beyond a screen for obstructive sleep apnea. The Multiple Sleep Latency Test that distinguishes narcolepsy and IH from other causes of EDS is a separate study with specific prerequisites that many providers don't order correctly.
- 02Cataplexy is missed because providers ask about 'fainting' or 'falling' rather than the specific emotion-triggered muscle weakness pattern. Patients describe knee buckling with laughter, neck weakness with anger, or facial drooping with strong emotion, and these episodes are not recognized as cataplexy.
- 03Sleep apnea is frequently coexistent with narcolepsy or IH and gets treated as the sole explanation. Patients are placed on CPAP, sleepiness persists, and the underlying narcolepsy or IH remains unidentified.
- 04The pharmacologic landscape — modafinil, armodafinil, sodium oxybate, pitolisant, solriamfetol, and the emerging orexin agonists — is complex and case-specific. Many patients are placed on one stimulant and never optimized.
The Ternary Health approach to Narcolepsy & Idiopathic Hypersomnia.
Audit the sleep architecture workup specifically — polysomnography followed by Multiple Sleep Latency Test under appropriate conditions, with attention to the prerequisites that are routinely violated and produce false-negative MSLTs.
Characterize cataplexy with structured clinical evaluation. Cataplexy presence distinguishes Type 1 from Type 2 narcolepsy and carries specific treatment implications. Many patients with cataplexy have never had it formally documented.
Evaluate comorbid sleep apnea, mood, and metabolic patterns — frequently coexistent and frequently the reason narcolepsy or IH gets missed or under-treated.
Audit the pharmacologic strategy across the full landscape — wake-promoting agents, sodium oxybate considerations, pitolisant, solriamfetol, and emerging orexin agonists — rather than accepting first-line stimulant monotherapy when the response is incomplete.
The Ternary Signal Library for Narcolepsy & Idiopathic Hypersomnia.
Our Signal Library for Narcolepsy & IH codifies the specific patterns that matter — sleep architecture and MSLT findings, cataplexy and orexin signals, comorbid mood and metabolic patterns, and pharmacologic response history. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.
- —Polysomnography — sleep stages, arousal pattern, sleep efficiency
- —MSLT mean sleep latency and SOREMP count
- —MSLT prerequisite compliance — sleep diary, actigraphy, prior PSG
- —Maintenance of Wakefulness Test where performed
- —Sleep apnea screening completeness
- —Structured cataplexy evaluation — emotion triggers and muscle groups
- —CSF orexin/hypocretin where measured
- —HLA-DQB1*0602 status where genotyped
- —Cataplexy frequency and severity documentation
- —Sleep paralysis and hypnagogic hallucination pattern
- —Depression and anxiety pattern — frequently misdiagnosed as cause of EDS
- —Sleep apnea evaluation — coexistent in substantial subset
- —Metabolic syndrome screening — narcolepsy-associated weight gain
- —ADHD-like cognitive symptoms
- —Restless legs and periodic limb movements
- —Wake-promoting agent trial history and response patterns
- —Sodium oxybate consideration and access barriers
- —Pitolisant and solriamfetol trial status
- —Stimulant tolerance, side effects, and contraindications
- —Combination therapy strategies attempted
How a Narcolepsy & Idiopathic Hypersomnia case moves through our workflow.
Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.
What you receive.
- —A written case synthesis covering sleep architecture, cataplexy status, and pharmacologic history
- —Integration of polysomnography, MSLT, comorbid workup, and medication trial findings into a single view
- —MSLT prerequisite and interpretation audit identifying whether retesting is warranted
- —Pharmacologic decision framework across wake-promoting agents, sodium oxybate, pitolisant, solriamfetol, and emerging orexin agonists
- —Clinical trial landscape review with eligibility considerations
- —Specialist identification for narcolepsy-experienced sleep medicine and any indicated comorbid workup
- —A written action plan and follow-up support as you implement it
What a Precision Deep Dive provides for Narcolepsy & Idiopathic Hypersomnia.
A Ternary Health Precision Deep Dive for narcolepsy and idiopathic hypersomnia evaluates the sleep architecture characterization, audits MSLT protocol and interpretation, characterizes cataplexy and other Type 1 features, synthesizes the pharmacologic evidence across modafinil, sodium oxybate, pitolisant, solriamfetol, and emerging orexin agonists, and addresses comorbid mood, autonomic, and metabolic considerations.
See the published sample reports · read the Ternary Method
What we look for alongside Narcolepsy & Idiopathic Hypersomnia.
Patients with Narcolepsy & Idiopathic Hypersomnia frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.
- Mood disorders
- Obstructive sleep apnea (frequently coexistent, not explanatory)
- Postural Orthostatic Tachycardia Syndrome
- ADHD-like cognitive presentation
What prospective Narcolepsy & Idiopathic Hypersomnia clients ask most.
Three ways to engage Ternary on Narcolepsy & Idiopathic Hypersomnia.
From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Narcolepsy & Idiopathic Hypersomnia.
Free Brief
A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.
Generated instantly, no charge.
Get a free Brief→Launchpad
A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.
Delivered in 3–5 business days
Start a Launchpad→Precision Deep Dive
A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.
September 2026 cohort
Apply for a Deep Dive→See exactly what you receive.
A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Narcolepsy & Idiopathic Hypersomnia — drawn from four research-validated patient profiles across four conditions.
Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.
Ready for clarity on your Narcolepsy & Idiopathic Hypersomnia?
Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Narcolepsy & Idiopathic Hypersomnia is generated instantly, no charge.